Novavax, Inc. NVAX

NAS: NVAX | ISIN: US6700024010   1/05/2025
6,410 USD (-3,90%)
(-3,90%)   1/05/2025

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows:

Conference call details:


Date:

May 8, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

https://emportal.ink/43UHjFq

Dial-in number:

(800) 836-8184 (Domestic) or


(+1) (646) 357-8785 (International)

Webcast:

ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

Replay details:


Date:

Available starting at 11:30 a.m. U.S. ET, May 8, 2025, until 11:59 p.m. U.S. ET, May 15, 2025

Dial-in number:

(888) 660-6345 (Domestic) or


(+1) (646) 517-4150 (International)

Passcode:

88407#

Webcast:

ir.novavax.com/events, until June 7, 2025

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors 
Luis Sanay, CFA
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-first-quarter-2025-financial-results-on-may-8-2025-302443439.html

SOURCE Novavax, Inc.

Novavax, Inc. in het nieuws

Mijn selecties